Open AccessUse of crizotinib for refractory ALK-positive lymphomas
Author(s) -
Anna Shcherbina,
В. В. Фоминых,
D. S. Abramov,
Natalia Myakova,
Michael Maschan,
Alexey Maschan
Publication year - 2017
Publication title -
terapevtičeskij arhiv
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.181
H-Index - 14
eISSN - 2309-5342
pISSN - 0040-3660
DOI - 10.17116/terarkh201789751-56
Subject(s) - crizotinib , medicine , refractory (planetary science) , anaplastic lymphoma kinase , lymphoma , positron emission tomography , oncology , hematopoietic stem cell transplantation , anaplastic large cell lymphoma , alk inhibitor , salvage therapy , chemotherapy , transplantation , nuclear medicine , lung cancer , physics , astrobiology , malignant pleural effusion
Aim. To evaluate the safety and efficacy of crizotinib used in pediatric patients with relapsed or refractory ALK-positive anaplastic large-cell lymphoma (ALCL). Subjects and methods. The paper describes the experience with crizotinib used in 8 patients with refractory ALK-ALCL before and after allogeneic hematopoietic stem cell transplantation (HSCT). Results. All the 8 (100%) patients treated with crizotinib were recorded to have complete responses, including complete metabolic ones (tumor disappearance as evidenced by positron emission tomography (PET)/computed tomography. Conclusion. Low and manageable toxicity of crizotinib and complete PET-negative responses in patients with resistant ALK lymphomas favor the need to test the drug as first-line therapy, by possibly decreasing the intensification of chemotherapy.